ISPOR - HPR23 Analysis of Clinical and Economic Evidence Focused on RWE in Medicare Drug Price Negotiations: Sacubitril/Valsartan, Rivaroxaban, and Apixaban

Full Text

HPR23 Analysis of Clinical and Economic Evidence Focused on RWE in Medicare Drug Price Negotiations: Sacubitril/Valsartan, Rivaroxaban, and Apixaban

Abstract

Authors

Phani Veeranki Kunal Paul Abhimanyu Roy Kirti Batra

Back to Volume 28, Supplemental Issue 12S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now